Airo launches inhalation system in the UK with SOMAÍ and IPS Pharma

Airo Brands and SOMAÍ have launched the AiroPro inhalation system in the United Kingdom, with IPS Pharma as exclusive distributor. The rollout gives UK pharmacies and healthcare providers access to a new cannabis inhalation platform built around EU-GMP extracts and proprietary vaporization technology.

Why it matters: - The launch expands access to inhalation-based cannabinoid products in the United Kingdom, one of Europe’s fastest-growing medical cannabis markets. - The rollout combines a U.S.-developed vaporization platform with EU-GMP-manufactured cannabinoid extracts and UK pharmaceutical distribution. - AiroPro adds another differentiated delivery format for patients and healthcare providers looking for consistent inhalation products.

What happened: - Airo Brands and SOMAÍ announced the launch of the AiroPro inhalation system in the United Kingdom on Oct. 27, 2026. - IPS Pharma will serve as the exclusive UK distributor for the Airo portfolio. - The system and compatible extracts are now available through UK pharmacies. - SOMAÍ is working exclusively with IPS Pharma to distribute Airo products to pharmacies and healthcare providers nationwide.

The details: - The launch pairs the AiroPro Inhalation Device, developed with Jupiter Research, with SOMAÍ’s EU-GMP inhalation extracts. - AiroPro is a closed-loop system in which the device and extracts are designed to work together. - Optimized airflow technology is designed to reduce clogging. - The ceramic atomizer is designed to deliver smooth, consistent inhalation while preserving each formulation’s terpene profile. - The device includes an ergonomic design, haptic feedback, and a long-lasting battery. - SOMAÍ manufactures the inhalation extracts at its EU-GMP facility in Lisbon, Portugal. - SOMAÍ uses purification processes that remove undesirable compounds while preserving cannabinoid integrity. - The manufacturing process is intended to support pharmaceutical-grade quality and batch-to-batch reproducibility. - The initial UK portfolio includes four formulations across two collections. - The Strain Series uses cannabis-derived terpene blends and includes NYC Diesel and Pink Rozay. - The Artisan Series uses naturally derived botanical terpenes and includes Lemon Cake and Mango Kush. - Additional products are planned for the coming months. - The launch follows SOMAÍ’s introduction of Airo products in Germany.

Between the lines: - The partnership shows how medical cannabis brands are leaning on regulated manufacturing and established pharmaceutical distribution to build trust in new markets. - The UK launch also reflects a broader push to move beyond standard cannabis formats and offer more controlled inhalation systems. - Airo’s international expansion signals that the company is positioning itself as a medical-grade cannabis technology brand, not just a U.S. vape brand. - SOMAÍ is using partnerships like this to extend its EU-GMP manufacturing platform into additional regulated markets.

What’s next: - Airo and SOMAÍ said additional products are planned in the UK in the coming months. - The companies will likely use the UK rollout to broaden access to differentiated inhalation products across other international medical markets. - IPS Pharma’s distribution network will be central to scaling availability through UK pharmacy and healthcare channels.

The bottom line: - Airo’s UK debut marks a push to bring pharmaceutical-style inhalation cannabis products to a market with growing demand for regulated, consistent delivery systems.